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Abstract
Aim: To evaluate the synergistic activity of antimicrobial drugs against
lineages of methicillin-resistant Staphylococcus aureus (MRSA) carrying SCCmec
IV. The biofilm production and related genes were also detected.
Methods and Results: Forty two MRSA isolates were tested for biofilm
production and related genes. Biofilm/biomass susceptibility to gentamicin (G),
linezolid (L), rifampicin (R) and vancomycin (V) was determined for six isolates
from three lineages prevalent in Rio de Janeiro hospitals in concentrations ranging
from 025 to 64 lg ml1. Biomass was evaluated by microtitre plate test and
number of viable cells (CFU cm2) and inspected by epifluorescence microscopy.
All isolates presented the icaA and sasG genes, but only 38% were biofilm producers.
There were 50 and 45% biomass reductions when concentrations ≥4 lg ml1 of R
or L and ≥16 lg ml1 of G or V, respectively, were used. Synergism tests produced
a 55% biomass reduction with R2lgml1 + G16lgml1 , R2lgml1 + L2lgml1 ,
R2lgml1 + V4lgml1 , and L2lgml1 + V4lgml1 . Number of viable cells was
reduced from 2 to 3 logs with R2lgml1 + L2lgml1 and R2lgml1 + V4lgml1 .
Conclusions: Synergisms involving R plus L and R plus V caused important
reductions in biofilm/biomass and the number of viable cells. Drug
combinations should be considered in the chemotherapies of MRSA-SCCmec
IV infections.
Significance and Impact of the Study: Biofilms in MRSA infections restrict the
clinical choice of antimicrobials. Thus, knowledge of the best options for
monotherapy and drug synergisms could improve clinical results.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a
major nosocomial pathogen (David and Daum 2010).
MRSA isolates present a penicillin-binding protein,
PBP2a, encoded by the mecA gene that is inserted in a
mobile genetic element called the staphylococcal cassette
chromosome mec (SCCmec) (Katayama et al. 2000).
Among the twelve different SCCmec allotypes already
described (IWG-SCC 2013), type IV, which is related to
the community isolates, has been emerging in hospitals
worldwide causing infections in patients with or without
traditional risk factors for MRSA (Schuenck et al. 2009;
Holzknecht et al. 2010; Lesosky et al. 2011; Caboclo et al.
2013; Velasco et al. 2012).
In Brazil, MRSA isolates related to the Brazilian ende-
mic clone (BEC)/sequence type (ST) 239 are traditionally
found in hospital-acquired infections (Santos et al. 1999).
However, over the last decade, changes in hospital epide-
miology have been observed, with the emergence of
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nosocomial infections caused by SCCmec IV isolates,
including such predominant lineages as USA400/ST1
(MW2 clone), USA1100/ST30 (Ocean Pacific clone) and
USA800/ST5 (paediatric clone) (Silva-Carvalho et al.
2009; Schuenck et al. 2012; Caboclo et al. 2013). Our
group showed the polyclonal emergency of nonmultiresis-
tant MRSA-SCCmec IV isolates in health-care-associated
infections causing deaths in patients in a hospital in Rio
de Janeiro (Schuenck et al. 2009).
Biofilm formation by Staph. aureus isolates is common
in medical devices such as catheters and prostheses,
allowing the pathogen to resist host immune responses
and antimicrobials (Donlan and Costerton 2002). How-
ever, some studies have shown that the majority of type
IV isolates do not produce biofilms or are weak or mod-
erate biofilm formers (Cha et al. 2011; Schuenck et al.
2012). Moreover, the action of antimicrobial agents either
individually or in combination against MRSA-SCCmec IV
isolates has not yet been analysed. Thus, this study aimed
to evaluate the activity of antimicrobial agents alone and
in various combinations against the biofilm/biomass pro-
duced by different lineages of MRSA-SCCmec IV isolates
from hospitals in Rio de Janeiro. Biofilm production and
related genes were also evaluated.
Materials and methods
Clinical isolates
Of a collection of 128 MRSA-SCCmec IV isolates previ-
ously characterized as to species (Bannerman and
Peacock 2007), methicillin resistance (CLSI 2012) and
SCCmec type (Milheirico et al. 2007), 42 were selected
for this study. This selection was based on the DNA poly-
morphism profiles determined by the pulsed-field gel
electrophoresis (PFGE) (Vivoni et al. 2006) and multilo-
cus sequence typing (MLST) methods (Enright et al.
2000). The lineages were classified according to McDou-
gal et al. (2003) as USA800/ST5 (14 isolates), USA400/
ST1 (9) and USA1100/ST30 (4); the remaining 15 isolates
belonged to other STs and/or clonalities. These isolates
were obtained between July 2004 and November 2008
from different clinical specimens from patients in eight
hospitals in Rio de Janeiro city (Table 1).
Biofilm/biomass formation assay
Biofilm/biomass formation was evaluated for all 42
MRSA-SCCmec IV isolates according to the microtitre
plate test protocol modified from that described by
Stepanovic et al. (2000). A bacterial suspension in Tryptic
Soy Broth (TSB, Merck, Alges, Portugal) supplemented
with 1% glucose and adjusted to a final concentration of
c. 1 9 107 cells ml1 was transferred to a microtitre plate
(200 ll per well). The plates were incubated aerobically
on a horizontal shaker at 120 rpm at 37°C. After 24 h,
the content of each well was removed and the wells were
washed twice with 200 ll of sterile water. The plates were
air-dried for 20 min, and bacterial biomass adhering to
the inner surfaces of each microtitre plate well was fixed
with 200 ll of 98% metanol (Vaz Pereira, Portugal) per
well during 15 min. Afterwards, the plates were emptied,
Table 1 General characteristics and biofilm formation ability of 42 MRSA-SCCmec IV isolates, positive for icaA and sasG genes, isolated from
hospitals in Rio de Janeiro
Sequence type
by MLST (n)
Clonality
by PFGE Clinical source (n) Biofilm production (n)
1 (9) USA400 Prosthesis secretion (3), urine (3), nasal (1), ear secretion (1),
bronchial alveolar lavage (1)
+ (1),  (8)
5 (14) USA800 Nasal (4), wound (4), prosthesis secretion (3),
bronchial alveolar lavage (2), blood (1)
++ (2), + (6),  (6)
30 (4) USA1100 Wound (2), bone secretion (1), renal abscess (1) + (2),  (2)
5 (2) ND Nasal (2), ++ (1), + (1)
1203 (2) ND Catheter tip (1), wound (1)  (2)
97 (3) ND Pleural fluid (1), nasal (2) ++ (1),  (2)
8 (1) USA 300 Wound ++
22 (1) EMRSA-15 Tracheal secretion 
45 (1) USA 600 Nasal 
72 (1) ND Blood 
2102 (1) ND Tracheal secretion 
714 (1) ND Wound +
30 (1) ND Bronchial alveolar lavage 
2112 (1) ND Nasal 
MLST, multilocus sequence typing; PFGE, pulsed-field gel electrophoresis; ND, not determined; strong biofilm producer (+++), moderate biofilm
producer (++), weak biofilm producer (+) and nonbiofilm producer ().
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left to dry for 20 min, and fixed biomass was stained for
5 min with 200 ll of crystal violet (CV) (Merck) per
well. Excess stain was rinsed off by placing the plate
under running tap water. After the plate was air-dried,
the dye bound to the adherent cells was resuspended with
200 ll of 33% (v/v) glacial acetic acid (Merck) per well.
The optical density (OD) of the obtained solution was
measured at 570 nm using a microtitre plate reader
(Tecan, Model Sunrise-basic Tecan, Gr€odig, Austria), and
the ability of Staph. aureus isolates to produce biofilm/
biomass was evaluated as OD570 values.
The Staphylococcus epidermidis strains, ATCC 35984
(strong biofilm producer) and ATCC12228 (nonbiofilm
producer) were used as controls. All isolates were classi-
fied in terms of their ability to form biofilm based on
absorbance values into the following categories: strong
producer (+++, OD > 20), moderate producer (++, OD
from 10 to 20), weak producer (+, OD from 05
to <10) and non producer (, OD < 05) of biofilm.
PCR method to detect biofilm-related genes
PCR was performed for the 42 MRSA-SCCmec IV isolates
to detect icaA (Mirani and Jamil 2011) and sasG (Roche
et al. 2003) genes, which encode a cell surface protein
related to biofilm and the polysaccharide intercellular
adhesin (PIA), respectively. The primer sequences used
were ICAAF – 50- AAACTTGGTGCGGTTACAGG-30 and
ICAAR – 50-TCTGGGCTTGACCATGTTG-30 (icaA gene),
and SASGF – 50-GAGATAAGAAAGGACCGG and SAS-
GR – TTAATTCTTTCTTCTACG-30 (sasG gene).
Bacterial biomass susceptibility testing
Biomass susceptibility to gentamicin (G), linezolid (L),
rifampicin (R) and vancomycin (V) (Sigma-Aldrich, St.
Louis, MO) were determined for six isolates selected from
three prevalent lineages: USA400/ST1 (isolates 633, weak
biofilm producer, and 915, nonproducer), USA800/ST5
(isolates 1112, weak biofilm producer, and 1177, moder-
ate biofilm producer) and USA1100/ST30 (isolates 943,
weak biofilm producer, and 1314, nonproducer). After
biomass formation for 24 h, the isolates were exposed to
antimicrobials, either individually or in combination,
with concentrations ranging from 025 to 64 lg ml1.
The concentrations used were based on the antimicrobial
break points (CLSI 2012). After antibiotic treatment for
24 h, the biofilms were characterized in terms of their
biomass through the microtitre plate test (above
described) and the number of cultivable cells, by plate
count agar (CFU cm2). To determine the number of
CFU, the biomass formed within the wells was removed
by rapid sonication for 6 min and, subsequently, serially
diluted. After plating the serial dilution on Tryptic Soy
Agar (TSA, Merck), the plates were incubated at 37°C, in
an aerobic incubator for 18 h prior to enumeration.
Statistical methods
Data were recorded as the mean standard deviation.
Because of the small sample size and the abnormal distri-
bution, the Kruskal–Wallis test was used for multiple
comparison analysis. Statistical significance was set at
P < 005. Data were analysed using SPSS 17.0 for Windows
(SPSS Inc., Chicago, IL).
Results
Biofilm formation assay and related genes
The biofilm production was considered positive only for
38% of MRSA-SCCmec IV isolates, being 8 USA800/ST5
isolates (six weak biofilm producers and two moderate),
1 USA400/ST1 isolate that was considered a weak biofilm
producer, 2 USA1100/ST30 isolates that were detected as
weak biofilm producers and five other isolates from other
clonalities were two weak biofilm producers and three
moderate (Table 1). The 42 MRSA isolates presented the
expected amplification bands of 751 bp and 300 bp for
icaA and sasG genes, respectively (data not shown).
Biomass susceptibility testing
To assess the activity of antimicrobials against biofilm/
biomass, drugs to which the MRSA-SCCmec IV isolates
presented susceptibility in disc diffusion tests (data not
shown) and that are usually indicated for treatment of
MRSA infections were selected (Colli et al. 2007). After
exposure to concentrations equal to or >4 lg ml1 of R
or L, a biomass reduction of 50% was observed. For G or
V, a reduction of about 45% was verified using concen-
trations ≥16 lg ml1 for all six MRSA-SCCmec IV
isolates evaluated, irrespective of the lineage (Fig. 1).
Regarding the cell viability analysis, which was deter-
mined by log CFU cm2, a reduction of up to 1 log for
V64lgml1 or R64lgml1 or 2 log for G64lgml1 or L64lgml1
was observed for all isolates (Fig. 2).
The synergism experiments showed a biomass reduction
of 55% for the antimicrobial associations Rif 2lgml1 +
Gen16lgml1 , Rif 2lgml1 + Lin2lgml1 , Rif 2lgml1 +
Van4lgml1 , and Lin2lgml1 + Van4lgml1 (Fig. 3), with
results equivalent to those obtained with the drugs used
alone but in higher concentrations (Fig. 4). In terms of cell
viability, the synergistic combinations were also more
effective when compared to the individual antimicrobial
tests, with reductions of 2–3 logs when the antimicrobial
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combinations Lin2lgml1 + Rif2lgml1 and Rif 2lgml1 +
Van4lgml1 were used (Fig. 5). Although an increased activ-
ity of some drug associations has been shown compared
with drugs alone against MRSA-SCCmec IV isolates, no
differences between lineages and between drugs used were
found (P > 005).
Discussion
Only a few studies have evaluated the action of different
antimicrobials against MRSA isolates, including those car-
rying SCCmec IV (Silva-Carvalho et al. 2009; Schuenck
et al. 2012). However, there are no studies that have evalu-
ated the combined action of antimicrobial agents against
certain MRSA-SCCmec IV lineages, which are nowadays
emerging in hospitals worldwide. In this study, for the first
time, the antimicrobial susceptibility of biofilm/biomass
produced by type IV lineages of MRSA that are becoming
prevalent in hospitals in Rio de Janeiro was evaluated.
Initially, our survey on biofilm formation found that
the different lineages of MRSA-SCCmec IV evaluated
were not strong biofilm producers. These results corre-
spond to studies of other authors that have shown that
the majority of type IV isolates are nonbiofilm producers
(Cha et al. 2011; Schuenck et al. 2012). Cha et al. (2011)
analysed 50 MRSA-type IV isolates and classified 86% as
nonbiofilm and weak biofilm producers. In a previous
study by our group, Schuenck et al. (2012) analysed 28
MRSA isolates from an orthopaedic hospital and classi-
fied all the type IV isolates (STs 1, 5 and 30) as weak or
moderate biofilm producers, whereas only the isolates
from the Brazilian clone/type III were considered to be
strong biofilm producers. In fact, according to Kaito
et al. (2011), MRSA-SCCmec IV isolates do not present a
psm-mec region in the mec cassette, which is related to a
higher capacity of biofilm formation. Additionally, in the
present study, the ST5 isolates showed a greater tendency
to be biofilm producers (eight isolates/n = 14) than the
Figure 1 Biomass evaluated after the use of increasing concentrations of antimicrobial agents (025–64 lg ml) for the six isolates from three
MRSA-SCCmec IV lineages in relation to the positive control (PC) without antimicrobial exposure. Filled squares, triangles and circles represent
633 (USA400/ST1), 1177 (USA800/ST5) and 943 (USA1100/ST30) biofilm producer isolates; open squares, circles and triangles represent 915
(US400/ST1) and 1314 (USA1100/ST30) nonbiofilm producer isolates, and 1112 (USA800/ST5) weak producer isolate. ( ) 633 (USA400/ST1);
( ) 915 (US400/ST1); ( ) 1177 (USA800/ST5); ( ) 1112 (USA800/ST5); ( ) 943 (USA1100/ST30) and ( )1314 (USA1100/ST30).
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isolates of ST1 lineage (1/9). This fact may be related to
the origin of this lineage (paediatric clone), indicating
that these isolates are more adapted to clinical environ-
ments. However, further studies involving more MRSA
isolates from this and other lineages and other regions
are necessary.
It is known that Staph. aureus has a great capacity to
bind to different surfaces, including plastics, maintaining
colonization through various forms of adhesins (Otto
2012). Thus, it was possible to evaluate the biomass
formed and the number of bacterial cells present there.
Furthermore, the action of the antimicrobials against the
biofilms/biomass was similar to all isolates, irrespective of
their ability to produce or not biofilm. Linezolid and rif-
ampicin antibiotics were observed to be better for reduc-
ing biomass than gentamicin or vancomycin ones.
Saginur et al. (2006) evaluated the biofilm antimicrobial
susceptibility of 12 MRSA isolates and found that
rifampicin was the single most active agent. Fernandez-
Barat et al. (2012) evaluated the effects of systemic treat-
ment with linezolid compared with vancomycin on bio-
film formation, in mechanically ventilated pigs with
severe MRSA-induced pneumonia. They observed that
the lowest bacterial burden was found in endotracheal
tubes treated with linezolid in comparison with the
untreated endotracheal tubes or with those treated with
vancomycin, confirming the findings of the present study.
The observations in the present study concerning the
limited activity of vancomycin against staphylococcal cells
embedded in biofilm/biomass are consistent with other
studies. (Raad et al. 2007; Wells et al. 2011). Wells et al.
(2011) evaluated the viability of staphylococcal cells in
mechanically dispersed biofilms and biomass formation
after treatment with vancomycin; in two biofilm producer
isolates cultivated in silk suture, a significant reduction in
cells viability was observed only at high concentrations of
Figure 2 Cell viability (log CFU cm2) evaluated after the use of increasing concentrations of antimicrobial agents (025–64 lg ml1) for the 6 iso-
lates from three MRSA-SCCmec IV lineages in relation to the positive control (PC) without antimicrobial exposure. Filled squares, triangles and circles
represent 633 (USA400/ST1), 1177 (USA800/ST5) and 943 (USA1100/ST30) biofilm producer isolates; open squares, circles and triangles represent
915 (US400/ST1) and 1314 (USA1100/ST30) nonbiofilm producer isolates, and 1112 (USA800/ST5) weak producer isolate. ( ) 633 (USA400/ST1);
( ) 915 (US400/ST1); ( ) 1177 (USA800/ST5); ( ) 1112 (USA800/ST5); ( ) 943 (USA1100/ST30) and ( )1314 (USA1100/ST30).
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the drug. However, no significant biomass reduction was
observed, even in concentrations of vancomycin
>20 lg ml1. According to Wells et al. (2011), some fac-
tors may contribute to differences in the antimicrobial
efficacy against biofilms/biomass, such as differences in
the penetration levels of the antimicrobials into the bio-
film/biomass, reduced bacterial growth rate and/or
increased expression of resistance genes.
In the present study, the synergic activity of antimicro-
bials was more effective in reducing both biomass and
number of viable cells than the drugs alone. Rifampicin
(2 lg ml1) plus linezolid (2 lg ml1) was one of the
most effective combinations, demonstrating an enhanced
antibacterial effect when compared to monotherapy.
According to a previous study, rifampicin is a constituent
of all the combinations that are active against MRSA and
is included in antibiotic therapy directed against biofilms/
biomass formed by these organisms (Saginur et al. 2006).
When the combination effect of oral antibiotics was eval-
uated for 33 biofilm-embedded MRSA isolates, rifampicin
(a) (b)
Figure 3 Biomass (a) and cell viability (log CFU cm2) (b) evaluated after the synergistic activity of antimicrobials at different concentrations
(lg ml1) for the six isolates from three MRSA-SCCmec IV lineages in relation to the positive control (PC) without antimicrobial exposure. G16–
16 lg ml1 of gentamicin; V4–4 lg ml
1 of vancomycin, L2–2 lg ml
1 of linezolid and R2–2 lg ml
1 of rifampicin. Grey bars represent the 633
(USA400/ST1) isolate, diagonal striped bars represent the 915 (USA400/ST1) isolate, black bars represent the 1177 (USA800/ST5) isolate, dotted
bars represent the 1112 (USA800/ST5) isolate, white bars represent the 943 (USA1100/ST30) isolate, and horizontal striped bars represent the
1314 (USA1100/ST30) isolate. ( ) 633 (USA400/ST1); ( ) 915 (US400/ST1); (■) 1177 (USA800/ST5); ( ) 1112 (USA800/ST5); (□) 943
(USA1100/ST30) and ( )1314 (USA1100/ST30).
Figure 4 Biomass reduction in six MRSA-SCCmec IV isolates exposed to different concentrations of antimicrobial agents applied individually or
combined, in relation to the positive control (PC) without antimicrobial exposure. V4–4 lg ml
1 of vancomycin, V64–64 lg ml
1 of vancomycin,
R2–2 lg ml
1 of rifampicin, R64–64 lg ml
1 of rifampicin, L2–2 lg ml
1 of linezolid, L64–64 lg ml
1 of linezolid. ( ) 633 (USA400/ST1); ( ) 915
(US400/ST1); (■) 1177 (USA800/ST5); ( ) 1112 (USA800/ST5); (□) 943 (USA1100/ST30) and ( )1314 (USA1100/ST30).
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plus linezolid had a better synergism than other antimi-
crobial combinations (Wu et al. 2012), which was verified
in the present study. Raad et al. (2007) demonstrated
that rifampicin was highly active when associated with
other antibiotics, particularly linezolid, in eradicating
MRSA colonization on silicone discs. Also, Vergidis et al.
(2011) demonstrated that combination treatment with
linezolid plus rifampin or vancomycin plus rifampin was
effective in an animal model of MRSA foreign body oste-
omyelitis in the context of retention of the infected for-
eign body. Although no significant differences have been
found, this antimicrobial combination presented P values
close to 005 in relation to the reduction in biomass and
to the viable cell number when compared with other
drug combinations. However, the reduced number of
MRSA isolates evaluated may have led to these findings,
and thus, further investigations involving more isolates
are necessary to confirm these results.
In our study, another synergism that was observed to
present a good activity against MRSA isolates was rifam-
picin (2 lg ml1) plus vancomycin (4 lg ml1). Reiter
et al. (2012) studied the activity of rifampicin, individu-
ally and in combination with vancomycin, against biofilm
producer isolates of MRSA. They found greater inhibition
of bacterial growth after combined drug use than after
use of each drug individually. However, the authors com-
mented that the noneradication of the biofilm/biomass
might contribute to bacterial persistence. Silva et al.
(2011) evaluated the synergic potential of subminimum
inhibitory concentrations of rifampicin plus vancomycin
against clinical isolates of MRSA and coagulase-negative
Staphylococcus. However, the authors observed a satis-
factory synergistic effect in only two and three of the 22
isolates that were evaluated, respectively.
In the present study, the combination between linezo-
lid and vancomycin against staphylococci biofilm/biomass
was not satisfactory, especially the ineffective reduction in
cell viability. Singh et al. (2009) observed that no syner-
gistic activity was seen when these two antimicrobial
agents were combined, in vitro, against five MRSA iso-
lates from bloodstream infections.
Microscopic analysis showed similar results to the in
vitro susceptibility tests, that is, only after exposure to
drug combinations, a decrease in the number of viable
cells was verified, as already observed by other authors
(Cha et al. 2011).
Schuenck et al. (2012) showed that all isolates of
MRSA were positive for the presence of the icaA gene,
confirming the findings of the present study. The sasG
gene was investigated by Rasmussen et al. (2013) who
found a correlation between invasive Staph. aureus iso-
lates and the presence of this gene. It is possible that the
polysaccharide intercellular adhesin (PIA), essential
substance in biofilm adhesion step, as well as, surface
proteins of staphylococci, such as SasG present in ica-
negative staphylococcal biofilms (Geoghegan et al. 2010),
have some participation in biomass formation and thus
contribute to the connection between cells on the mate-
rial surface.
In summary, this study showed that MRSA-SCCmec IV
isolates are, in general, weak or nonbiofilm producers
and lineages belonging to STs 1, 5 and 30, irrespective of
biofilm production, presented biomass reduction after
exposure to different antimicrobials. Furthermore, anti-
microbial synergisms involving Rif2lgml1 + Lin2lgml1
and Rif2lgml1 + Van4lgml1 appear to be good therapy
choices, as both combinations produced greater reduc-
tions in biomass and the number of viable staphylococcal
Figure 5 Cell viability (CFU cm2) reduction in six MRSA-SCCmec IV isolates exposed to different concentrations of antimicrobial agents applied
individually or combined, in relation to the positive control (PC) without antimicrobial exposure. V4–4 lg ml
1 of vancomycin, V64–64 lg ml
1 of
vancomycin, R2–2 lg ml
1 of rifampicin, R64–64 lg ml
1 of rifampicin, L2–2 lg ml
1 of linezolid, L64–64 lg ml
1 of linezolid. ( ) 633 (USA400/
ST1); ( ) 915 (US400/ST1); (■) 1177 (USA800/ST5); ( ) 1112 (USA800/ST5); (□) 943 (USA1100/ST30) and ( )1314 (USA1100/ST30).
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cells. Therefore, these synergistic drug combinations
might be considered in the chemotherapy of MRSA-
SCCmec IV infections.
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